Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R44DK139877-02
Description
SBIR Phase Phase II award: "Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development" awarded to XYLYX BIO, INC. in BROOKLYN, New York. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $967,715. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.gov